

December 30, 2025

Name of listed company: Chugai Pharmaceutical Co., Ltd.
Code number: 4519 (Prime Market of Tokyo Stock Exchange)
Head office: 1-1, Nihonbashi-Muromachi 2-Chome, Chuo-ku,
Tokyo
President & CEO: Osamu Okuda
Inquiries to: Kae Miyata
Head of Corporate Communications Dept.
Tel:
For media: +81-(0)3-3273-0881
For investors: +81-(0)3-3273-0554

[Update on Disclosed Matter] Notice Concerning Completion of Making Renalys Pharma, Inc. a Wholly-Owned Subsidiary and an Absorption-Type Merger

TOKYO, December 30, 2025 – [Chugai Pharmaceutical Co., Ltd.](https://www.chugai-pharm.co.jp/english/news/detail/20251118173000_1199.html) made Renalys Pharma, Inc. a wholly-owned subsidiary on November 27, 2025, as previously announced in the news release titled "Notice of Absorption-Type Merger of a Wholly-Owned Subsidiary, Renalys Pharma, Inc." issued on November 18, 2025. Following this, Chugai announced that the absorption-type merger, with Chugai as the surviving company and Renalys Pharma, Inc. as the dissolving company, was completed on December 30, 2025.

[Reference]

Notice of Absorption-Type Merger of a Wholly-Owned Subsidiary, Renalys Pharma, Inc. (News release issued on November 18, 2025)

https://www.chugai-pharm.co.jp/english/news/detail/20251118173000_1199.html

###